Excellent response to rituximab in a patient with recalcitrant epidermolysis bullosa acquisita: a case report

Epidermolysis Bullosa Acquisita is a rare, chronic autoimmune blistering disorder characterized by vesicles and bullae on the skin and mucous membranes. This condition, presenting typically in adulthood, is caused by autoantibodies against type VII collagen. Conventional treatments, including systemic corticosteroids and immunosuppressants, often fail to achieve long-term remission. Biologic agents like rituximab have shown promise in managing refractory cases. This report presents a case of a 27-year-old female with recalcitrant epidermolysis bullosa acquisita successfully managed after starting rituximab therapy.